Medium‑Chain Triglyceride–Supplemented Ketogenic Diet in Parkinson’s Disease: A Small Randomized Feasibility Trial and What It Means for Clinical Practice
Posted inClinical Updates Wellness & Lifestyle

Medium‑Chain Triglyceride–Supplemented Ketogenic Diet in Parkinson’s Disease: A Small Randomized Feasibility Trial and What It Means for Clinical Practice

A randomized, double‑blind pilot tested an MCT‑supplemented ketogenic diet (MCT‑KD) in 16 people with moderate Parkinson’s disease. The diet was feasible and acceptable, induced nutritional ketosis by day 4, produced metabolic benefits and nonmotor symptom improvement, but did not change a primary mobility endpoint (TUG) over three weeks.
Posted inClinical Updates Wellness & Lifestyle

Ketogenic Diet vs Further Antiseizure Medication in Infants with Drug-Resistant Epilepsy: What the KIWE Trial Adds to Clinical Practice

The KIWE randomised trial (Lancet Neurol 2023) found no superiority of a classic ketogenic diet over an additional antiseizure medication for seizure frequency in infants (1–24 months) with drug‑resistant epilepsy; tolerability and safety profiles were similar, supporting the diet as a viable treatment option.